MedTrace Logo

A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis

NCT03688555 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-04-11

Study results available
· View outcomes & findings →

Summary

The study will evaluate the effect of ACT-774312 on the nasal polyps and will assess the safety and tolerability of ACT-774312 in the patients with bilateral nasal polyposis

Conditions

  • Bilateral Nasal Polyposis

Interventions

DRUG

ACT-774312

ACT-774312 will be available as hard gelatin capsules containing 200 mg of ACT-774312

DRUG

Placebo

Matching placebo hard gelatin capsules

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Idorsia Pharmaceuticals Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-19
Primary Completion
2020-11-24
Completion
2020-12-01

Countries

  • Belgium
  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03688555 on ClinicalTrials.gov